【Drug Name】

Generic Name：Methylprednisolone Sodium Succinate for Injection

English Name：Methylprednisolone Sodium Succinate for Injection

Pinyin：Zhusheyong Jiaponilong Huposuanna

【Ingredients】

The active ingredient of this product is methylprednisolone sodium succinate.

【Indications】

This product is indicated for anti-inflammatory treatment of various conditions, including: rheumatic diseases such as post-traumatic osteoarthritis, synovitis from osteoarthritis, rheumatoid arthritis (including juvenile rheumatoid arthritis), acute or subacute bursitis, epicondylitis, acute nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, and ankylosing spondylitis; collagen diseases (immune complex disorders) such as systemic lupus erythematosus (including lupus nephritis), acute rheumatic carditis, systemic dermatomyositis (polymyositis), polyarteritis nodosa, and Goodpasture’s syndrome; severe dermatological diseases such as pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis, mycosis fungoides, and urticaria; severe allergic conditions that are unresponsive to conventional therapy and impair function, including bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, transfusion-related urticaria-like reactions, and acute non-infectious laryngeal edema (epinephrine is first-line in this case); severe acute and chronic allergic or inflammatory ophthalmic diseases such as herpes zoster ophthalmicus, iritis, iridocyclitis, chorioretinitis, diffuse posterior uveitis and choroiditis, optic neuritis, and sympathetic ophthalmia; gastrointestinal diseases in critical stages such as ulcerative colitis and regional enteritis; respiratory diseases including sarcoidosis, berylliosis, fulminant or disseminated pulmonary tuberculosis (with appropriate antitubercular chemotherapy), Löffler’s syndrome not responding to other therapies, and aspiration pneumonitis; and edematous states such as nephrotic syndrome (without uremia) caused by idiopathic or lupus-related nephropathy. It is also indicated as an immunosuppressive agent in organ transplantation, and for the treatment of blood disorders and malignancies, including autoimmune hemolytic anemia, adult idiopathic thrombocytopenic purpura (IV use only), secondary thrombocytopenia in adults, erythroblastopenia, and congenital hypoplastic anemia. It is also used for palliative treatment of adult leukemia and lymphoma, and childhood acute leukemia. In shock, it is used in cases of adrenal insufficiency or shock unresponsive to conventional therapy (hydrocortisone is typically used; methylprednisolone may be used when mineralocorticoid activity is not desired), including hemorrhagic, traumatic, and surgical shock. Though large-scale clinical studies are lacking, animal data suggest that methylprednisolone may benefit shock cases unresponsive to standard treatments like fluid resuscitation. It is also used in neurological conditions such as cerebral edema from primary or metastatic tumors, surgery, or radiotherapy; traumatic brain edema; acute exacerbations of multiple sclerosis; acute spinal cord injury (treatment should begin within 8 hours of injury); in combination with antitubercular agents for tuberculous meningitis with or at risk of subarachnoid blockage; trichinosis with neurological or myocardial involvement; and for prevention of chemotherapy-induced nausea and vomiting. Endocrine indications include primary or secondary adrenocortical insufficiency, acute adrenocortical insufficiency (hydrocortisone or cortisone are preferred, but synthetic glucocorticoids may be added as needed), treatment during major trauma or illness in patients with known or suspected adrenal insufficiency, congenital adrenal hyperplasia, non-suppurative thyroiditis, and hypercalcemia of malignancy.

【Manufacturer】

Company Name：Fuan Pharmaceutical Group Hubei Renming Pharmaceutical Co., Ltd

Address：No.1, Qijiashan, Baiquan, Dongxihu District, Wuhan City, Hubei Provice, P.R.C